Tradename: ELEVIDYS
Proper Name: delandistrogene moxeparvovec-rokl
Indication: Indicated for treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
Approval Date: 06/22/2023
Manufacturer: Sarepta Therapeutics, Inc.
More: https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/elevidys